Article
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy.
Nature cancer - 1 Dec 2021
Samstein Robert M, Krishna Chirag, Ma Xiaoxiao, Pei Xin, Lee Ken-Wing, Makarov Vladimir, Kuo Fengshen, Chung Jonathan, Srivastava Raghvendra M, Purohit Tanaya A, Hoen Douglas R, Mandal Rajarsi, Setton Jeremy, Wu Wei, Shah Rachna, Qeriqi Besnik, Chang Qing, Kendall Sviatoslav, Braunstein Lior, Weigelt Britta, Blecua Carrillo Albornoz Pedro, Morris Luc G T, Mandelker Diana L, Reis-Filho Jorge S, de Stanchina Elisa, Powell Simon N, Chan Timothy A, Riaz Nadeem
Abstract excerpt
Immune checkpoint blockade (ICB) has improved outcomes for patients with advanced cancer, but the determinants of response remain poorly understood. Here we report differential effects of mutations in the homologous recombination genes BRCA1 and BRCA2 on response to ICB in mouse and human tumors, and further show that truncating mutations in BRCA2 are associated with superior response compared to those in BRCA1....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.